Given the central role of RAS signaling in embryonal RMS (eRMS) pathogenesis [17], a recombinant myxoma virus (MYXV) armed with CRISPR/Cas9 gene-editing tools was engineered to target activated NRAS genes in eRMS tumors specifically. This evidence concerns the gene NRAS and embryonal rhabdomyosarcoma.